Please login to the form below

Not currently logged in
Email:
Password:

Type 2 diabetes market set to hit $39bn by 2021

Grwoth expected to come from new treatments and the condtion's rising prevalence

Diabetes insulinThe global market for type 2 diabetes treatments is set to grow by 66% over the next seven years, according to analysts.

GBI Research predicts its value will rise from $23.5bn in 2014 to $39bn by 2021, driven by the condition's rising prevalence and continued uptake of recently approved treatments.

In particular its new report points to three classes of drugs: dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium–glucose cotransporter 2 inhibitors. DPP-4 inhibitors are already a widely-used class of drugs, led by Merck & Co's Januvia (sitagliptin), and the class is poised to see newer entrants from the likes of Merck and Takeda.

Newer versions of glucagon-like peptide-1 (GLP-1) receptor agonists are also in the offing from Novo Nordisk and Sanofi, while sodium–glucose cotransporter 2 inhibitors have starting reaching the market, led by Janssen's Invokana (canagliflozin).

GBI Research also expects the type 2 diabetes market to see a lift from a number of pipeline treatments that offer improvements in dosing frequency and administration methods.

Fiona Chisholm, associate analyst for GBI Research, said: “In comparison to many previously marketed therapies, several recently approved and pipeline treatments provide beneficial effects, such as improved weight control and lowered hypoglycemia risk, and offer improvements in dosing frequency and administration methods.

“Notable examples include two recently approved once-weekly GLP-1 receptor agonists, Tanzeum and Trulicity, and an orally administered GLP-1 receptor agonist, OG-217SC, which is in phase II development, as well as ITCA 650, a sub-dermally administered osmotic pump in phase III development that requires once or twice-yearly dosing.”

The analysts also said that the late-stage pipeline of potential new treatments for type 2 diabetes is looking healthy, with 16 products at the pre-registration phase and 33 products in phase III.

Casting its eye over where market growth will come from, GBI says the expansion will be seen in countries such as France, Germany, Italy, Spain and the UK - Europe's biggest markets, as well as Canada, Japan and the all important US market.

Article by
Dominic Tyer

24th July 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...
Generation Z
The roaring ‘20s and Generation Z
How a new generation will shape pharma comms this decade...

Infographics